<DOC>
	<DOCNO>NCT00003893</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . It yet know regimen chemotherapy plus radiation therapy effective early-stage breast cancer . PURPOSE : Randomized phase III trial compare effectiveness two different regimen adjuvant chemotherapy plus radiation therapy treat woman early-stage breast cancer .</brief_summary>
	<brief_title>Adjuvant Chemotherapy Plus Radiation Therapy Treating Women With Early-Stage Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect synchronous vs sequential adjuvant chemotherapy radiotherapy local recurrence , disease-free overall survival , treatment delay woman early-stage breast cancer . - Compare safety regimen , term dose intensity toxicity , patient population . - Compare quality life cosmetic outcome patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord clinical oncologist , axillary clearance ( yes v ) , radiotherapy boost intent ( boost v boost ) , chemotherapy intent ( cyclophosphamide , methotrexate , fluorouracil [ 5-FU ] v anthracycline-containing regimen ) . Patients randomize one two treatment arm . Patients receive chemotherapy regimen include cyclophosphamide , methotrexate , 5-FU . Some regimen may also include epirubicin , doxorubicin , mitoxantrone , and/or mitomycin . Chemotherapy repeat every 3 week 4-8 course . - Arm I ( synchronous chemoradiotherapy ) : Patients receive synchronous therapy receive chemotherapy regimen plus daily radiotherapy course 2 3 OR course 5 6 chemotherapy . Radiotherapy administer 3-5 week . - Arm II ( sequential chemoradiotherapy ) : Patients receive sequential therapy receive chemotherapy regimen follow daily radiotherapy begin completion chemotherapy ( course 6 8 ) . Radiotherapy administer 3-5 week . Treatment arm continue absence disease progression unacceptable toxicity . Quality life assess chemotherapy , 2-3 week completion treatment , 1 , 2 , 5 year . Patients follow annually 10 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 2,250 patient ( 1,125 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer Earlystage disease No metastatic disease Complete surgical excision tumor Planned use adjuvant chemotherapy radiotherapy If participate cosmetic outcome evaluation portion study , must unilateral disease Hormone receptor status Not specify PATIENT CHARACTERISTICS : Age : Not specify Sex : Female Menopausal status : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Bone marrow function adequate Hepatic : Hepatic function adequate Renal : Renal function adequate Cardiovascular : Cardiac function adequate Other : No prior malignancy except basal cell squamous cell skin cancer carcinoma situ No medical social condition would preclude study compliance Fit receive adjuvant chemotherapy radiotherapy ( administer either synchronously sequentially ) Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior chemotherapy No concurrent epirubicin doxorubicin study combination chemotherapy regimen Endocrine therapy : Prior concurrent hormonal therapy allow No concurrent tamoxifen treated methotrexate , mitomycin , mitoxantrone study combination chemotherapy regimen Radiotherapy : See Disease Characteristics No concurrent internal mammary chain irradiation No concurrent orthovoltage irradiation whole breast Surgery : See Disease Characteristics Recovered prior surgery Other : Concurrent participation another clinical trial allow</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>stage I breast cancer</keyword>
</DOC>